Ladenburg Thalmann Initiates Coverage On NeuroBo Pharmaceuticals with Buy Rating, Announces Price Target of $6
Ladenburg Thalmann analyst Aydin Huseynov initiates coverage on NeuroBo Pharmaceuticals (NASDAQ:NRBO) with a Buy rating and announces Price Target of $6.